Platelet treatment guidance method based on drug gene polymorphism and thrombelastogram

Abstract

The invention relates to the technical field of platelets, in particular to a platelet treatment guidance method based on drug gene polymorphism and a thrombelastogram. The platelet treatment guidance method based on the drug gene polymorphism and the thrombelastogram comprises the following steps of S1, carrying out drug gene detection; S2, sequencing a whole blood genome DNA; S3, carrying out metabolism type classification; S4, carrying out TEG detection; and S5, carrying out result analysis. According to the platelet treatment guidance method based on the drug gene polymorphism and the thrombelastogram, the risk of a new stroke within 90 days can be effectively reduced by guiding light ischemic stroke antiplatelet treatment according to the drug gene polymorphism in combination with TEG, and the bleeding risk is not increased; patients insensitive to the anti-platelet drug treatment can be found in time through combination of the gene detection and the TEG, a new basis can be provided for selection of anti-platelet treatment drugs, and ischemic stroke patients can select the anti-platelet drugs more accurately and reasonably, so that an individualized anti-platelet treatment scheme is formulated, the risk of relapse of the stroke is effectively reduced, and the method has important guiding significance on secondary prevention of the ischemic stroke and is worthy of clinical popularization and application.

Description

technical field [0001] The invention relates to the technical field of platelets, in particular to a platelet treatment guidance method based on drug gene polymorphism and thromboelastogram. Background technique [0002] Patients with minor ischemic stroke are at high short-term risk of subsequent stroke, which is likely to result in disability, especially in the first 90 days after stroke. The CHANCE study found that administration of aspirin combined with clopidogrel within 24 hours after minor ischemic stroke or transient ischemic attack (TIA) for 21 days could reduce the risk of stroke recurrence by 32% compared with aspirin alone, and did not increase bleeding complications. The secondary analysis of the POINT study also confirmed that the use of dual-antibody therapy in the first 21 days after the onset of disease has the greatest benefit in reducing ischemic events, and the benefit of continuing to use dual-antibody therapy after 21 days will be offset by the increase...

AI Technical Summary

Problems solved by technology

The mechanism of AR and CR is relatively complicated, and it is not very clear at present. Previous studies have shown that related gene polymorphisms involved in the metabolism and action of antiplatelet drugs may be an important factor

At present, there is no individualized and standardized antiplatelet therapy system based on the condition of Chinese people in China